help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 9, 1010-1017, October 2006; doi:10.1634/theoncologist.11-9-1010
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Challenges in the Use of Epidermal Growth Factor Receptor Inhibitors in Col...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Cutsem, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Cutsem, E.

Special Section on Colorectal Cancer

Challenges in the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer

Eric Van Cutsem

Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium

Key Words. Epidermal growth factor receptor • Monoclonal antibody • Cetuximab • Panitumumab • Rash • Tyrosine kinase inhibitors

Correspondence: Eric Van Cutsem, M.D., Ph.D., Digestive Oncology Unit, University Hospital Gasthuisberg/Leuven, Herestraat 49, 3000 Leuven, Belgium. Telephone: +32 16 34 4218; Fax: +32 16 34 4419; e-mail: Eric.VanCutsem{at}uz.kuleuven.ac.be

Novel targeted agents increase the therapeutic armamentarium in metastatic colorectal cancer (mCRC). Monoclonal antibodies against the epidermal growth factor receptor (EGFR) are active against EGFR-expressing mCRC that is refractory to irinotecan. EGFR monoclonal antibodies also have promise in less advanced stages of CRC. Cetuximab and panitumumab are clearly active agents. It has been shown that cetuximab is more active when administered in combination with irinotecan. Phase II studies also report promising activity when monoclonal antibodies against the EGFR are combined with classic chemotherapeutic regimens in the first-line treatment of mCRC. However, the best means of scheduling such agents and integrating them with each other and with chemotherapy have yet to be established. The management of toxicity (particularly rash) and finding appropriate means of selecting patients pose additional challenges. While the occurrence of rash is associated with greater likelihood of response, EGFR staining by immunohistochemistry at baseline is not. For reasons that are not yet clear, the tyrosine kinase inhibitors of EGFR seem less effective than their monoclonal antibody counterparts in the therapy of mCRC.




This article has been cited by other articles:


Home page
 The OncologistHome page
R. M. Giusti, K. A. Shastri, M. H. Cohen, P. Keegan, and R. Pazdur
FDA Drug Approval Summary: Panitumumab (VectibixTM)
Oncologist, May 1, 2007; 12(5): 577 - 583.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Johnston
The Colorectal Cancer Coalition: Reflections on the Future
Oncologist, October 1, 2006; 11(9): 970 - 972.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2006 by AlphaMed Press.